Call Our HELPLINE: 1-800-4PD-INFO (473-4636)

Update on Tozadenant Trial for Parkinson’s

On 11/20/17, Acorda Therapeutics, Inc. announced that it is discontinuing the tozadenant clinical trial.  They concluded that they could not be confident that weekly white blood cell count screening would sufficiently ensure patient safety.


On 11/15/17, Acorda Therapeutics, Inc. announced that several people living with Parkinson's who participated in the Phase III trial for tozadenant experienced agranulocytosis — a severe drop in the number of white blood cells which fight infection — leading to cases of sepsis and five fatalities. Participants in the trial will now have blood cell count monitoring increased from monthly to weekly.  The study has paused new enrollment in the long-term safety studies, pending further discussion with the independent Data Safety Monitoring Board (DSMB) and the United States Food and Drug Administration (FDA).

Tozadenant is an oral adenosine A2a receptor antagonist currently in Phase III development as an adjunctive treatment to levodopa in Parkinson’s disease patients to reduce OFF time.

Statement from the Parkinson’s Foundation

Our thoughts are with the family members who lost a loved one enrolled in this trial. Their participation in clinical research will ultimately help make life better for the people diagnosed with Parkinson's in the future. 

The Parkinson’s Foundation remains confident that Acorda and the FDA will investigate this rare event. Clinical trials in Parkinson’s disease — from oral therapies to surgical treatments — have had a strong safety record and they are critical in testing the safety and efficacy of investigational therapies.

In order to discover new PD therapies, we rely on brave and altruistic people, like the ones in this trial, to participate in clinical research. The Parkinson’s Foundation remains committed to supporting clinical research through our global network of Centers of Excellence and Parkinson’s Advocates in Research.

If you would like more information about the benefits and risks of clinical trial participation, learn more here.  If you have questions or concerns, please call our toll-free Helpline at 1-800-4PD-INFO (473-4636).

Thursday, November 16, 2017
Bal du Printemps Honors Supporters, Raises $460,000 for Research
Thursday, May 21, 2015

One hundred and seventy-five guests attended the annual Bal du Printemps Galapresented by the Parkinson’s Disease Foundation (PDF) at The Metropolitan Club in New York City on Tuesday, May 19, 2015 for an intimate and important evening.Willie Geist, co-anchor of NBC News’ “Today” and co-host of MSNBC’s “Morning Joe,” served as the Master of Ceremonies for the evening.

Parkinson’s Disease Foundation Announces New Members of People with Parkinson’s Advisory Council
Tuesday, May 12, 2015

The Parkinson’s Disease Foundation® (PDF®) is pleased to announce new members of its People with Parkinson’s Advisory Council. The council is made up of people living with Parkinson’s disease and care partners who help drive PDF’s goals of ending the disease and supporting those affected by it.

The National Parkinson Foundation Welcomes Two New Board Members
Monday, April 6, 2015

MIAMI,FL — The National Parkinson Foundation (NPF) announced the election of two new members to its Board of Directors: Gregory E. Katz and Jonathan Levin.

Rasheda Ali Joins Moving Day® Tampa
Monday, March 16, 2015

Rasheda Ali Joins Tampa Bay Residents to Get "Moving" for Parkinson's Disease

The National Parkinson Foundation Invests in the Future of Parkinson's Research
Monday, March 2, 2015

Support Provided for the Next Generation of Movement Disorder Neurologists

The National Parkinson Foundation Welcomes New Board Member
Wednesday, February 18, 2015

MIAMI, FL — The National Parkinson Foundation (NPF) announced the election of Ricardo Caporal to its Board of Directors. 

National Parkinson Foundation Expands Expert Care Network
Wednesday, February 11, 2015

UC San Diego Health System Designated Center of Excellence 

Erin Borger and Paul Blom Join NPF's Board of Directors
Tuesday, January 13, 2015

MIAMI,FL — The National Parkinson Foundation (NPF) announced the election of two new members to its Board of Directors: Erin R. Borger and Paul R. Blom. 

FDA Approves Revolutionary Parkinson's Treatment and NPF Is Helping Deliver it to You
Monday, January 12, 2015

The National Parkinson Foundation (NPF) is pleased to share that the U.S. Food and Drug Administration (FDA) has approved DUOPA™, developed by AbbVie Inc., as a treatment for people with advanced Parkinson's disease.

Pages

mail icon

Subscribe to get the latest news on treatments, research and other updates.